In The News

Top Scientist Has Discovered A BRILLIANT COVID Treatment!

Over the last several weeks, the news has been in hyperdrive reporting on the Delta Variant that is sweeping the world. These fearmongers are working double-time to push people into receiving the vaccine to protect themselves but in the same breath say that the vaccine won’t completely protect them.

There have been doctors and even the drug companies that are making these so-called vaccines telling people, including Dr. Fauci, that those receiving the jab are most likely spreading the virus. However, no one will hear it and they continue to line up as the sheep they are to get the jab instead of doing any actual research on it at all.

I don’t know about you but I would be extremely sure before I stuck something in my body considering how much controversy is swirling arou9nd it, right?

Since this virus reared its ugly head early last year, people immediately searched for ways to beat it and one was found but Big Pharma was not happy about it at all.

The cheap and effective drug Ivermectin has shown tremendous results in treating COVID-19, but as you know a vicious smear campaign ensued shortly after it was even mentioned to the public. Fancy that.

This brings us to what is happening in Israel currently.

As you may have heard, Israel is in the midst of a huge outbreak and it is important to mention that they are among the most vaccinated for COVID-19 countries in the world.

Now a recent study from Israel may reveal an answer to their problems and possibly everyone else’s too.

 

From The Jerusalem Post:

Ivermectin, a drug used to fight parasites in third-world countries, could help reduce the length of infection for people who contract coronavirus for less than a $1 a day, according to recent research by Sheba Medical Center in Tel Hashomer.
Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba, conducted a randomized, controlled, double-blinded trial from May 15, 2020, through the end of January 2021 to evaluate the effectiveness of ivermectin in reducing viral shedding among nonhospitalized patients with mild to moderate COVID-19.
Ivermectin has been approved by the US Food and Drug Administration since 1987. The drug’s discoverers were awarded the 2015 Nobel Prize in medicine for its treatment of onchocerciasis, a disease caused by infection with a parasitic roundworm.
Over the years, it has been used for other indications, including scabies and head lice. Moreover, in the last decade, several clinical studies have started to show its antiviral activity against viruses ranging from HIV and the flu to Zika and West Nile.
The drug is also extremely economical. A study published in the peer-reviewed American Journal of Therapeutics showed that the cost of ivermectin for other treatments in Bangladesh is around $0.60 to $1.80 for a five-day course. It costs up to $10 a day in Israel, Schwartz said.
In Schwartz’s study, some 89 eligible volunteers over the age of 18 who were diagnosed with coronavirus  and staying in state-run COVID-19 hotels were divided into two groups: 50% received ivermectin, and 50% received a placebo, according to their weight. They were given the pills for three days in a row, an hour before a meal.
The volunteers were tested using a standard nasopharyngeal swab PCR test with the goal of evaluating whether there was a reduction in viral load by the sixth day – the third day after termination of the treatment. They were swabbed every two days.
Nearly 72% of volunteers treated with ivermectin tested negative for the virus by day six. In contrast, only 50% of those who received the placebo tested negative.
IN ADDITION, the study looked at culture viability, meaning how infectious the patients were, and found that only 13% of ivermectin patients were infectious after six days, compared with 50% of the placebo group – almost four times as many.
“Our study shows first and foremost that ivermectin has antiviral activity,” Schwartz said. “It also shows that there is almost a 100% chance that a person will be noninfectious in four to six days, which could lead to shortening isolation time for these people. This could have a huge economic and social impact.”
The study appeared on the MedRxiv health-research sharing site. It has not yet been peer reviewed.
Schwartz said other similar studies – though not all of them conducted to the same double-blind and placebo standards as his – also showed a favorable impact of ivermectin treatment.
His study did not prove ivermectin was effective as a prophylactic, meaning that it could prevent disease, he cautioned, nor did it show that it reduces the chances of hospitalization. However, other studies have shown such evidence, he added.
To Top